Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.

Literature DB >> 31415061

Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.

Feng Wang¹, Qi Zhao¹, Ying-Nan Wang¹, Ying Jin¹, Ming-Ming He¹, Ze-Xian Liu¹, Rui-Hua Xu¹.

Abstract

Entities: Disease Gene

Year: 2019 PMID： 31415061 PMCID： PMC6696731 DOI： 10.1001/jamaoncol.2019.2963

Source DB: PubMed Journal: JAMA Oncol ISSN： 2374-2437 Impact factor: 31.777

Keyword Cloud
Cited

× No keyword cloud information.

105 in total

1. Therapeutic targeting of the DNA damage response in prostate cancer.

Authors: Catherine H Marshall; Emmanuel S Antonarakis
Journal: Curr Opin Oncol Date: 2020-05 Impact factor: 3.645

2. Anlotinib suppresses MLL-rearranged acute myeloid leukemia cell growth by inhibiting SETD1A/AKT-mediated DNA damage response.

Authors: Jinzhu Chen; Juan Feng; Zhihong Fang; Jing Ye; Qinwei Chen; Qiuling Chen; Kai Chen; Xiaoming Xiong; Guowei Li; Haihan Song; Bing Xu
Journal: Am J Transl Res Date: 2021-03-15 Impact factor: 4.060

Review 3. [Predictive diagnostics for checkpoint inhibitors].

Authors: Hans-Ulrich Schildhaus; Wilko Weichert
Journal: Pathologe Date: 2021-05-06 Impact factor: 1.011

4. Mutational Characteristics of Primary Mucosal Melanoma: A Systematic Review.

Authors: Olivia Beaudoux; Jean-Baptiste Oudart; Laurence Riffaud; Laetitia Visseaux; Aude Marchal; Anne-Sophie Lebre; Florent Grange
Journal: Mol Diagn Ther Date: 2022-02-23 Impact factor: 4.074

5. Exceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report.

Authors: Baorang Zhu; Ying Liu; Jing Li; Liyan Diao; Lin Shao; Han Han-Zhang; Lu Zhang; Qiaolin Kang; Wuwei Yang
Journal: Oncologist Date: 2019-12-17

Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.

1. Therapeutic targeting of the DNA damage response in prostate cancer.

2. Anlotinib suppresses MLL-rearranged acute myeloid leukemia cell growth by inhibiting SETD1A/AKT-mediated DNA damage response.

Review 3. [Predictive diagnostics for checkpoint inhibitors].

4. Mutational Characteristics of Primary Mucosal Melanoma: A Systematic Review.

5. Exceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report.

Review 6. Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers.

7. A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.

Review 8. POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes.

Review 9. Immune Checkpoint Inhibitors in Prostate Cancer.

10. Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.